Asset Management One Co. Ltd. Buys 47,524 Shares of Johnson & Johnson $JNJ

Asset Management One Co. Ltd. grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,256,031 shares of the company’s stock after acquiring an additional 47,524 shares during the period. Johnson & Johnson comprises approximately 0.7% of Asset Management One Co. Ltd.’s investment portfolio, making the stock its 19th biggest holding. Asset Management One Co. Ltd. owned approximately 0.05% of Johnson & Johnson worth $232,893,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in JNJ. Brighton Jones LLC lifted its position in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares during the last quarter. United Bank boosted its stake in shares of Johnson & Johnson by 110.7% during the 1st quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after acquiring an additional 4,876 shares in the last quarter. MBB Public Markets I LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter valued at about $325,000. HFM Investment Advisors LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter valued at about $836,000. Finally, AAF Wealth Management LLC boosted its position in Johnson & Johnson by 6.3% during the first quarter. AAF Wealth Management LLC now owns 1,810 shares of the company’s stock worth $300,000 after purchasing an additional 107 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $204.85 on Wednesday. The firm has a 50 day moving average of $201.80 and a two-hundred day moving average of $183.84. The stock has a market capitalization of $493.53 billion, a PE ratio of 19.77, a P/E/G ratio of 2.10 and a beta of 0.34. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $215.18.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion for the quarter. On average, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research analyst reports. Argus set a $210.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Raymond James Financial lifted their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a report on Wednesday, October 15th. JPMorgan Chase & Co. increased their target price on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Tuesday, September 16th. UBS Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Monday. Finally, Guggenheim upped their target price on Johnson & Johnson from $206.00 to $227.00 and gave the company a “buy” rating in a report on Friday, December 5th. Four analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $212.62.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Positive Phase 2 SLE results — J&J reported topline JASMINE data showing nipocalimab met primary and key secondary endpoints, with signals of steroid‑sparing benefit; the company plans a Phase 3 program, which could materially expand future immunology revenue if confirmed. Johnson & Johnson unveils new data showing nipocalimab …
• Positive Sentiment: Media coverage of the encouraging nipocalimab data highlights clinical momentum and investor interest in the program, supporting sentiment around J&J’s R&D pipeline. Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment
• Positive Sentiment: Regulatory progress in oncology — J&J submitted an application to the European Medicines Agency for TECVAYLI (teclistamab) plus DARZALEX subcutaneous for relapsed/refractory multiple myeloma; approval would extend the commercial runway for its bispecific/platform combos. Johnson & Johnson submits application to the European Medicines Agency …
• Positive Sentiment: Analyst upgrades/support — Wolfe Research raised its price target to $240 and kept an outperform stance, and Scotiabank maintained a buy rating; both moves can lift investor confidence and provide near‑term support. Wolfe Research adjusts PT on Johnson & Johnson to $240 …
• Neutral Sentiment: Comparative/sector commentary — Analyst pieces contrasting JNJ with AstraZeneca and highlighting AI adoption frame J&J as a diversified, defensive healthcare pick; useful context but not immediate catalysts. JNJ vs. AZN: Which Drug Stock Comes Out on Top for Investors?
• Neutral Sentiment: Seasonal/market commentary — Articles note potential flu‑season tailwinds for vaccine/shot market exposure and thematic AI interest in medtech names; these are background positives but uncertain in magnitude. Flu Season’s Here—This Dividend-Payer Controls the Shot Market (JNJ)
• Negative Sentiment: Short‑term volatility — JNJ recently experienced a pullback (reported prior session decline), illustrating trader profit‑taking despite positive headlines; that volatility can cap upside until new fundamental catalysts arrive. Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.